Sandoz

Sandoz is the global leader in generic and biosimilar medicines, specializing in the development and commercialization of high-quality, affordable off-patent pharmaceuticals. Originally a division of Novartis, Sandoz became an independent, publicly traded company in October 2023. The company's portfolio includes approximately 1,500 products that reach over 500 million patients annually. Sandoz is a pioneer in the biosimilars industry, having launched the world's first biosimilar (Omnitrope) in 2006. Its business is structured into two main segments: Generics (including oral solids, injectables, and anti-infectives) and Biosimilars. The company is currently focused on expanding its high-value biosimilar pipeline to drive long-term growth and increase patient access to critical biologic therapies.